Buying These 3 Stocks Is Like Making a Bet in a Burning House
Aegerion Pharmaceuticals, MannKind Corp., and VIVUS, Inc. have all attracted short sellers in droves this year. With each company facing serious headwinds, should investors avoid these struggling biotechs?
Why Is George Soros Buying This Beaten Down Biotech Stock?
Soros Fund Management opened a position in the struggling biotech Aegerion Pharmaceuticals in the third quarter, even while the drugmaker's revenue estimates continued to plummet. Should retail investors follow his lead into this beaten down biotech?
The Best Healthcare Stocks of 2014: Which Is Our Favorite for 2015?
In this week's Industry Focus, our analysts discuss their favorites of the successful 2014 healthcare large-cap stocks.